Roche Holding AG’s Japanese affiliate Chugai Pharmaceutical Co., Ltd. has obtained regulatory approval in short order from Japan’s Ministry of Health, Labour and Welfare for the monoclonal antibody combination casirivimab/imdevimab, as Ronapreve, for SARS-CoV-2 infection.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?